Intrexon Corp (XON) Given “Buy” Rating at Stifel Nicolaus

Intrexon Corp (NYSE:XON)‘s stock had its “buy” rating restated by research analysts at Stifel Nicolaus in a report released on Tuesday. They presently have a $57.00 target price on the biotechnology company’s stock. Stifel Nicolaus’ target price suggests a potential upside of 180.79% from the stock’s current price.

A number of other equities research analysts have also weighed in on the company. Wunderlich decreased their target price on Intrexon Corp from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, March 14th. Northland Securities initiated coverage on Intrexon Corp in a research report on Thursday, December 29th. They set an “outperform” rating and a $40.00 target price for the company. Finally, JMP Securities set a $42.00 target price on Intrexon Corp and gave the company a “buy” rating in a research report on Friday, February 3rd. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Intrexon Corp has a consensus rating of “Buy” and an average target price of $41.67.

Analyst Recommendations for Intrexon Corp (NYSE:XON)

Intrexon Corp (NYSE:XON) opened at 20.30 on Tuesday. The company has a 50-day moving average of $20.56 and a 200-day moving average of $24.71. Intrexon Corp has a one year low of $18.41 and a one year high of $32.90. The company’s market cap is $2.41 billion.

Intrexon Corp (NYSE:XON) last issued its earnings results on Wednesday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.14. The firm had revenue of $46 million for the quarter, compared to the consensus estimate of $52.53 million. Intrexon Corp had a negative net margin of 93.97% and a negative return on equity of 18.46%. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period last year, the firm earned ($0.28) earnings per share. Equities research analysts expect that Intrexon Corp will post ($0.89) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally published by BBNS and is the property of of BBNS. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://baseballnewssource.com/markets/intrexon-corp-xon-earns-buy-rating-from-stifel-nicolaus-updated/577101.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XON. MSI Financial Services Inc raised its position in Intrexon Corp by 15.9% in the third quarter. MSI Financial Services Inc now owns 12,580 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 1,725 shares during the last quarter. Penn Davis Mcfarland Inc. bought a new position in Intrexon Corp during the third quarter valued at approximately $258,000. Sanders Morris Harris Inc. raised its position in Intrexon Corp by 10.5% in the third quarter. Sanders Morris Harris Inc. now owns 93,940 shares of the biotechnology company’s stock valued at $2,632,000 after buying an additional 8,940 shares during the last quarter. Commonwealth Equity Services Inc raised its position in Intrexon Corp by 65.3% in the third quarter. Commonwealth Equity Services Inc now owns 21,172 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 8,366 shares during the last quarter. Finally, Capital Fund Management S.A. raised its position in Intrexon Corp by 67.9% in the third quarter. Capital Fund Management S.A. now owns 109,011 shares of the biotechnology company’s stock valued at $3,054,000 after buying an additional 44,084 shares during the last quarter. 84.51% of the stock is owned by hedge funds and other institutional investors.

About Intrexon Corp

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

5 Day Chart for NYSE:XON

Receive News & Ratings for Intrexon Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp and related companies with our FREE daily email newsletter.

 

Latest News

Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Colorado Rockies Bullpen Helping Them to NL West Lead
Colorado Rockies Bullpen Helping Them to NL West Lead
Hall of Famer Given New Lease on Life
Hall of Famer Given New Lease on Life
New York Mets Have the Power
New York Mets Have the Power
Red Sox Fighting Through Illness and Injury
Red Sox Fighting Through Illness and Injury
Cleveland and Arizona Off to Fast Starts
Cleveland and Arizona Off to Fast Starts


Leave a Reply

 
© 2006-2017 BBNS.